nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—lung cancer—thyroid cancer	0.787	1	CtDrD
Pemetrexed—GART—saliva-secreting gland—thyroid cancer	0.00412	0.0995	CbGeAlD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.0034	0.0803	CbGpPWpGaD
Pemetrexed—GART—trachea—thyroid cancer	0.00318	0.0768	CbGeAlD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.00273	0.0646	CbGpPWpGaD
Pemetrexed—GART—thyroid gland—thyroid cancer	0.00252	0.0607	CbGeAlD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.00239	0.0563	CbGpPWpGaD
Pemetrexed—GART—head—thyroid cancer	0.00223	0.0539	CbGeAlD
Pemetrexed—SLC46A1—thyroid gland—thyroid cancer	0.00204	0.0493	CbGeAlD
Pemetrexed—SLC46A1—Iron uptake and transport—CP—thyroid cancer	0.0019	0.045	CbGpPWpGaD
Pemetrexed—DHFR—saliva-secreting gland—thyroid cancer	0.00188	0.0454	CbGeAlD
Pemetrexed—SLC46A1—head—thyroid cancer	0.00181	0.0437	CbGeAlD
Pemetrexed—ATIC—thyroid gland—thyroid cancer	0.00171	0.0412	CbGeAlD
Pemetrexed—DCK—saliva-secreting gland—thyroid cancer	0.00163	0.0393	CbGeAlD
Pemetrexed—GART—lymph node—thyroid cancer	0.00156	0.0377	CbGeAlD
Pemetrexed—ATIC—head—thyroid cancer	0.00152	0.0366	CbGeAlD
Pemetrexed—DHFR—G1/S-Specific Transcription—CDK1—thyroid cancer	0.00145	0.0343	CbGpPWpGaD
Pemetrexed—DHFR—trachea—thyroid cancer	0.00145	0.035	CbGeAlD
Pemetrexed—TYMS—Erlotinib—Vandetanib—thyroid cancer	0.00133	0.376	CbGdCrCtD
Pemetrexed—SLC29A1—trachea—thyroid cancer	0.00131	0.0317	CbGeAlD
Pemetrexed—SLC29A1—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00131	0.0309	CbGpPWpGaD
Pemetrexed—SLC46A1—lymph node—thyroid cancer	0.00127	0.0306	CbGeAlD
Pemetrexed—TYMS—G1/S-Specific Transcription—CDK1—thyroid cancer	0.00127	0.03	CbGpPWpGaD
Pemetrexed—DCK—trachea—thyroid cancer	0.00126	0.0303	CbGeAlD
Pemetrexed—TYMS—thyroid gland—thyroid cancer	0.00116	0.028	CbGeAlD
Pemetrexed—DHFR—thyroid gland—thyroid cancer	0.00115	0.0277	CbGeAlD
Pemetrexed—ATIC—lymph node—thyroid cancer	0.00106	0.0256	CbGeAlD
Pemetrexed—SLC29A1—thyroid gland—thyroid cancer	0.00104	0.0251	CbGeAlD
Pemetrexed—TYMS—head—thyroid cancer	0.00103	0.0248	CbGeAlD
Pemetrexed—DHFR—head—thyroid cancer	0.00102	0.0246	CbGeAlD
Pemetrexed—DCK—thyroid gland—thyroid cancer	0.000993	0.024	CbGeAlD
Pemetrexed—SLC29A1—head—thyroid cancer	0.000922	0.0222	CbGeAlD
Pemetrexed—DHFR—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.000884	0.0209	CbGpPWpGaD
Pemetrexed—DCK—head—thyroid cancer	0.000881	0.0213	CbGeAlD
Pemetrexed—TYMS—Afatinib—Vandetanib—thyroid cancer	0.000872	0.246	CbGdCrCtD
Pemetrexed—DHFR—E2F mediated regulation of DNA replication—CDK1—thyroid cancer	0.000855	0.0202	CbGpPWpGaD
Pemetrexed—TYMS—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.000771	0.0182	CbGpPWpGaD
Pemetrexed—TYMS—Gefitinib—Vandetanib—thyroid cancer	0.000762	0.215	CbGdCrCtD
Pemetrexed—TYMS—E2F mediated regulation of DNA replication—CDK1—thyroid cancer	0.000746	0.0176	CbGpPWpGaD
Pemetrexed—TYMS—lymph node—thyroid cancer	0.00072	0.0174	CbGeAlD
Pemetrexed—DHFR—lymph node—thyroid cancer	0.000713	0.0172	CbGeAlD
Pemetrexed—SLC29A1—lymph node—thyroid cancer	0.000646	0.0156	CbGeAlD
Pemetrexed—DCK—lymph node—thyroid cancer	0.000617	0.0149	CbGeAlD
Pemetrexed—GART—Metabolism—MINPP1—thyroid cancer	0.000538	0.0127	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.00049	0.0116	CbGpPWpGaD
Pemetrexed—GART—Folate Metabolism—TP53—thyroid cancer	0.000466	0.011	CbGpPWpGaD
Pemetrexed—GART—Metabolism—NDUFA13—thyroid cancer	0.000457	0.0108	CbGpPWpGaD
Pemetrexed—DHFR—E2F transcription factor network—CDK1—thyroid cancer	0.000453	0.0107	CbGpPWpGaD
Pemetrexed—DHFR—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—AKT1—thyroid cancer	0.000445	0.0105	CbGpPWpGaD
Pemetrexed—GART—Metabolism—CHST14—thyroid cancer	0.00043	0.0101	CbGpPWpGaD
Pemetrexed—Hypertension—Vandetanib—thyroid cancer	0.000418	0.00333	CcSEcCtD
Pemetrexed—Infestation—Sorafenib—thyroid cancer	0.000418	0.00333	CcSEcCtD
Pemetrexed—Infestation NOS—Sorafenib—thyroid cancer	0.000418	0.00333	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.000415	0.0033	CcSEcCtD
Pemetrexed—Chest pain—Vandetanib—thyroid cancer	0.000413	0.00329	CcSEcCtD
Pemetrexed—Arthralgia—Vandetanib—thyroid cancer	0.000413	0.00329	CcSEcCtD
Pemetrexed—Acute coronary syndrome—Sorafenib—thyroid cancer	0.000412	0.00328	CcSEcCtD
Pemetrexed—Renal failure—Sorafenib—thyroid cancer	0.000411	0.00327	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00041	0.00327	CcSEcCtD
Pemetrexed—Myocardial infarction—Sorafenib—thyroid cancer	0.00041	0.00327	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00041	0.00326	CcSEcCtD
Pemetrexed—Stomatitis—Sorafenib—thyroid cancer	0.000408	0.00325	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—NKX2-1—thyroid cancer	0.000403	0.00951	CbGpPWpGaD
Pemetrexed—Embolism—Doxorubicin—thyroid cancer	0.000398	0.00317	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Sorafenib—thyroid cancer	0.000396	0.00315	CcSEcCtD
Pemetrexed—Oedema—Vandetanib—thyroid cancer	0.000396	0.00315	CcSEcCtD
Pemetrexed—TYMS—E2F transcription factor network—CDK1—thyroid cancer	0.000395	0.00934	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.000394	0.0093	CbGpPWpGaD
Pemetrexed—Infection—Vandetanib—thyroid cancer	0.000393	0.00313	CcSEcCtD
Pemetrexed—Thrombosis—Epirubicin—thyroid cancer	0.000391	0.00311	CcSEcCtD
Pemetrexed—Nervous system disorder—Vandetanib—thyroid cancer	0.000388	0.00309	CcSEcCtD
Pemetrexed—Thrombocytopenia—Vandetanib—thyroid cancer	0.000387	0.00308	CcSEcCtD
Pemetrexed—Skin disorder—Vandetanib—thyroid cancer	0.000384	0.00306	CcSEcCtD
Pemetrexed—ATIC—Metabolism—MINPP1—thyroid cancer	0.000373	0.0088	CbGpPWpGaD
Pemetrexed—Urinary tract disorder—Sorafenib—thyroid cancer	0.000371	0.00295	CcSEcCtD
Pemetrexed—Neuritis—Epirubicin—thyroid cancer	0.00037	0.00295	CcSEcCtD
Pemetrexed—Urethral disorder—Sorafenib—thyroid cancer	0.000368	0.00293	CcSEcCtD
Pemetrexed—Thrombosis—Doxorubicin—thyroid cancer	0.000361	0.00288	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00036	0.00287	CcSEcCtD
Pemetrexed—SLC29A1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000358	0.00845	CbGpPWpGaD
Pemetrexed—SLC29A1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000358	0.00845	CbGpPWpGaD
Pemetrexed—Erythema multiforme—Sorafenib—thyroid cancer	0.000355	0.00283	CcSEcCtD
Pemetrexed—Dyspnoea—Vandetanib—thyroid cancer	0.000353	0.00281	CcSEcCtD
Pemetrexed—Dyspepsia—Vandetanib—thyroid cancer	0.000348	0.00277	CcSEcCtD
Pemetrexed—SLC29A1—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000347	0.0082	CbGpPWpGaD
Pemetrexed—GART—Metabolism—HPGD—thyroid cancer	0.000346	0.00818	CbGpPWpGaD
Pemetrexed—Decreased appetite—Vandetanib—thyroid cancer	0.000344	0.00274	CcSEcCtD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.000344	0.00811	CbGpPWpGaD
Pemetrexed—Neuritis—Doxorubicin—thyroid cancer	0.000343	0.00273	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000342	0.00272	CcSEcCtD
Pemetrexed—Fatigue—Vandetanib—thyroid cancer	0.000341	0.00272	CcSEcCtD
Pemetrexed—SLC46A1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—thyroid cancer	0.000339	0.008	CbGpPWpGaD
Pemetrexed—Pain—Vandetanib—thyroid cancer	0.000338	0.00269	CcSEcCtD
Pemetrexed—Constipation—Vandetanib—thyroid cancer	0.000338	0.00269	CcSEcCtD
Pemetrexed—Arrhythmia—Sorafenib—thyroid cancer	0.000336	0.00267	CcSEcCtD
Pemetrexed—Alopecia—Sorafenib—thyroid cancer	0.000332	0.00264	CcSEcCtD
Pemetrexed—DHFR—G1/S Transition—CDK1—thyroid cancer	0.000329	0.00776	CbGpPWpGaD
Pemetrexed—Erythema—Sorafenib—thyroid cancer	0.000327	0.0026	CcSEcCtD
Pemetrexed—Malnutrition—Sorafenib—thyroid cancer	0.000327	0.0026	CcSEcCtD
Pemetrexed—Neoplasm malignant—Epirubicin—thyroid cancer	0.000324	0.00258	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000323	0.00258	CcSEcCtD
Pemetrexed—Dysgeusia—Sorafenib—thyroid cancer	0.00032	0.00255	CcSEcCtD
Pemetrexed—ATIC—Metabolism—NDUFA13—thyroid cancer	0.000317	0.00748	CbGpPWpGaD
Pemetrexed—Body temperature increased—Vandetanib—thyroid cancer	0.000313	0.00249	CcSEcCtD
Pemetrexed—Abdominal pain—Vandetanib—thyroid cancer	0.000313	0.00249	CcSEcCtD
Pemetrexed—DHFR—Metabolism of nitric oxide—AKT1—thyroid cancer	0.000308	0.00728	CbGpPWpGaD
Pemetrexed—Rectal haemorrhage—Epirubicin—thyroid cancer	0.000306	0.00244	CcSEcCtD
Pemetrexed—Anaemia—Sorafenib—thyroid cancer	0.000302	0.00241	CcSEcCtD
Pemetrexed—DCK—Doxorubicin—Epirubicin—thyroid cancer	0.0003	0.0847	CbGdCrCtD
Pemetrexed—Lacrimation increased—Epirubicin—thyroid cancer	0.0003	0.00239	CcSEcCtD
Pemetrexed—Neoplasm malignant—Doxorubicin—thyroid cancer	0.0003	0.00238	CcSEcCtD
Pemetrexed—ATIC—Metabolism—CHST14—thyroid cancer	0.000298	0.00703	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TRIM24—thyroid cancer	0.000295	0.00696	CbGpPWpGaD
Pemetrexed—Syncope—Sorafenib—thyroid cancer	0.000293	0.00233	CcSEcCtD
Pemetrexed—Leukopenia—Sorafenib—thyroid cancer	0.000293	0.00233	CcSEcCtD
Pemetrexed—Creatinine increased—Epirubicin—thyroid cancer	0.00029	0.00231	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—MINPP1—thyroid cancer	0.00029	0.00686	CbGpPWpGaD
Pemetrexed—Loss of consciousness—Sorafenib—thyroid cancer	0.000287	0.00229	CcSEcCtD
Pemetrexed—TYMS—G1/S Transition—CDK1—thyroid cancer	0.000287	0.00678	CbGpPWpGaD
Pemetrexed—Asthenia—Vandetanib—thyroid cancer	0.000284	0.00226	CcSEcCtD
Pemetrexed—Rectal haemorrhage—Doxorubicin—thyroid cancer	0.000283	0.00225	CcSEcCtD
Pemetrexed—Hypertension—Sorafenib—thyroid cancer	0.000282	0.00225	CcSEcCtD
Pemetrexed—Pruritus—Vandetanib—thyroid cancer	0.00028	0.00223	CcSEcCtD
Pemetrexed—Myalgia—Sorafenib—thyroid cancer	0.000278	0.00222	CcSEcCtD
Pemetrexed—Arthralgia—Sorafenib—thyroid cancer	0.000278	0.00222	CcSEcCtD
Pemetrexed—DCK—Epirubicin—Doxorubicin—thyroid cancer	0.000278	0.0784	CbGdCrCtD
Pemetrexed—Lacrimation increased—Doxorubicin—thyroid cancer	0.000278	0.00221	CcSEcCtD
Pemetrexed—SLC46A1—Disease—CHST14—thyroid cancer	0.000277	0.00654	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CDK1—thyroid cancer	0.000277	0.00654	CbGpPWpGaD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000276	0.0022	CcSEcCtD
Pemetrexed—Ventricular tachycardia—Epirubicin—thyroid cancer	0.000276	0.0022	CcSEcCtD
Pemetrexed—Pulmonary embolism—Epirubicin—thyroid cancer	0.000276	0.0022	CcSEcCtD
Pemetrexed—Diarrhoea—Vandetanib—thyroid cancer	0.000271	0.00216	CcSEcCtD
Pemetrexed—Creatinine increased—Doxorubicin—thyroid cancer	0.000269	0.00214	CcSEcCtD
Pemetrexed—SLC29A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000268	0.00633	CbGpPWpGaD
Pemetrexed—Anaphylactic shock—Sorafenib—thyroid cancer	0.000267	0.00212	CcSEcCtD
Pemetrexed—Colitis—Epirubicin—thyroid cancer	0.000265	0.00211	CcSEcCtD
Pemetrexed—Infection—Sorafenib—thyroid cancer	0.000265	0.00211	CcSEcCtD
Pemetrexed—Skin exfoliation—Epirubicin—thyroid cancer	0.000264	0.0021	CcSEcCtD
Pemetrexed—SLC46A1—Disease—TRIM33—thyroid cancer	0.000263	0.0062	CbGpPWpGaD
Pemetrexed—Shock—Sorafenib—thyroid cancer	0.000263	0.00209	CcSEcCtD
Pemetrexed—Nervous system disorder—Sorafenib—thyroid cancer	0.000262	0.00208	CcSEcCtD
Pemetrexed—Dizziness—Vandetanib—thyroid cancer	0.000262	0.00208	CcSEcCtD
Pemetrexed—Thrombocytopenia—Sorafenib—thyroid cancer	0.000261	0.00208	CcSEcCtD
Pemetrexed—Neuropathy—Epirubicin—thyroid cancer	0.00026	0.00207	CcSEcCtD
Pemetrexed—Skin disorder—Sorafenib—thyroid cancer	0.000259	0.00206	CcSEcCtD
Pemetrexed—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.000256	0.00204	CcSEcCtD
Pemetrexed—Pulmonary embolism—Doxorubicin—thyroid cancer	0.000256	0.00204	CcSEcCtD
Pemetrexed—Anorexia—Sorafenib—thyroid cancer	0.000254	0.00203	CcSEcCtD
Pemetrexed—Oesophagitis—Epirubicin—thyroid cancer	0.000253	0.00201	CcSEcCtD
Pemetrexed—Vomiting—Vandetanib—thyroid cancer	0.000252	0.002	CcSEcCtD
Pemetrexed—SLC46A1—Folate Metabolism—TP53—thyroid cancer	0.000251	0.00594	CbGpPWpGaD
Pemetrexed—Rash—Vandetanib—thyroid cancer	0.000249	0.00199	CcSEcCtD
Pemetrexed—Dermatitis—Vandetanib—thyroid cancer	0.000249	0.00198	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—NDUFA13—thyroid cancer	0.000247	0.00583	CbGpPWpGaD
Pemetrexed—Colitis—Doxorubicin—thyroid cancer	0.000246	0.00196	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.000246	0.0058	CbGpPWpGaD
Pemetrexed—Skin exfoliation—Doxorubicin—thyroid cancer	0.000244	0.00194	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000243	0.00194	CcSEcCtD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDK1—thyroid cancer	0.000242	0.00571	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—HPGD—thyroid cancer	0.00024	0.00567	CbGpPWpGaD
Pemetrexed—Neuropathy—Doxorubicin—thyroid cancer	0.00024	0.00191	CcSEcCtD
Pemetrexed—Sepsis—Epirubicin—thyroid cancer	0.00024	0.00191	CcSEcCtD
Pemetrexed—Dyspnoea—Sorafenib—thyroid cancer	0.000238	0.00189	CcSEcCtD
Pemetrexed—Nausea—Vandetanib—thyroid cancer	0.000235	0.00187	CcSEcCtD
Pemetrexed—Dyspepsia—Sorafenib—thyroid cancer	0.000235	0.00187	CcSEcCtD
Pemetrexed—DHFR—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000235	0.00554	CbGpPWpGaD
Pemetrexed—Oesophagitis—Doxorubicin—thyroid cancer	0.000234	0.00186	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—CHST14—thyroid cancer	0.000232	0.00548	CbGpPWpGaD
Pemetrexed—Decreased appetite—Sorafenib—thyroid cancer	0.000232	0.00185	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00023	0.00183	CcSEcCtD
Pemetrexed—Fatigue—Sorafenib—thyroid cancer	0.00023	0.00183	CcSEcCtD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000229	0.00542	CbGpPWpGaD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000229	0.00542	CbGpPWpGaD
Pemetrexed—Pain—Sorafenib—thyroid cancer	0.000228	0.00182	CcSEcCtD
Pemetrexed—Constipation—Sorafenib—thyroid cancer	0.000228	0.00182	CcSEcCtD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000226	0.00533	CbGpPWpGaD
Pemetrexed—Sepsis—Doxorubicin—thyroid cancer	0.000222	0.00177	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—PCM1—thyroid cancer	0.00022	0.00518	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000218	0.00174	CcSEcCtD
Pemetrexed—Renal failure acute—Epirubicin—thyroid cancer	0.000217	0.00173	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.000214	0.00506	CbGpPWpGaD
Pemetrexed—Urticaria—Sorafenib—thyroid cancer	0.000212	0.00169	CcSEcCtD
Pemetrexed—Abdominal pain—Sorafenib—thyroid cancer	0.000211	0.00168	CcSEcCtD
Pemetrexed—Body temperature increased—Sorafenib—thyroid cancer	0.000211	0.00168	CcSEcCtD
Pemetrexed—TYMS—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000205	0.00484	CbGpPWpGaD
Pemetrexed—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000205	0.00163	CcSEcCtD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000204	0.00482	CbGpPWpGaD
Pemetrexed—Renal failure acute—Doxorubicin—thyroid cancer	0.000201	0.0016	CcSEcCtD
Pemetrexed—GART—Metabolism—TPR—thyroid cancer	0.000199	0.0047	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Sorafenib—thyroid cancer	0.000197	0.00157	CcSEcCtD
Pemetrexed—GART—Metabolism—PRKAR1A—thyroid cancer	0.000196	0.00462	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—MINPP1—thyroid cancer	0.000194	0.00457	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—PCM1—thyroid cancer	0.000192	0.00452	CbGpPWpGaD
Pemetrexed—Asthenia—Sorafenib—thyroid cancer	0.000191	0.00152	CcSEcCtD
Pemetrexed—Mood swings—Epirubicin—thyroid cancer	0.00019	0.00151	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000189	0.00151	CcSEcCtD
Pemetrexed—Pruritus—Sorafenib—thyroid cancer	0.000189	0.0015	CcSEcCtD
Pemetrexed—Blood creatinine increased—Epirubicin—thyroid cancer	0.000188	0.0015	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—HPGD—thyroid cancer	0.000187	0.00442	CbGpPWpGaD
Pemetrexed—Dehydration—Epirubicin—thyroid cancer	0.000187	0.00149	CcSEcCtD
Pemetrexed—Diarrhoea—Sorafenib—thyroid cancer	0.000183	0.00145	CcSEcCtD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000182	0.0043	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000182	0.0043	CbGpPWpGaD
Pemetrexed—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—thyroid cancer	0.000182	0.00429	CbGpPWpGaD
Pemetrexed—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000181	0.00144	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000181	0.00144	CcSEcCtD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000179	0.00423	CbGpPWpGaD
Pemetrexed—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000177	0.00141	CcSEcCtD
Pemetrexed—Dizziness—Sorafenib—thyroid cancer	0.000176	0.00141	CcSEcCtD
Pemetrexed—Mood swings—Doxorubicin—thyroid cancer	0.000176	0.0014	CcSEcCtD
Pemetrexed—SLC46A1—Disease—TCF7L1—thyroid cancer	0.000175	0.00414	CbGpPWpGaD
Pemetrexed—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000174	0.00138	CcSEcCtD
Pemetrexed—Dysphagia—Epirubicin—thyroid cancer	0.000173	0.00138	CcSEcCtD
Pemetrexed—Dehydration—Doxorubicin—thyroid cancer	0.000173	0.00137	CcSEcCtD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000172	0.00406	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.00017	0.00401	CbGpPWpGaD
Pemetrexed—Pancreatitis—Epirubicin—thyroid cancer	0.00017	0.00135	CcSEcCtD
Pemetrexed—Vomiting—Sorafenib—thyroid cancer	0.00017	0.00135	CcSEcCtD
Pemetrexed—Angina pectoris—Epirubicin—thyroid cancer	0.000169	0.00135	CcSEcCtD
Pemetrexed—Rash—Sorafenib—thyroid cancer	0.000168	0.00134	CcSEcCtD
Pemetrexed—Dermatitis—Sorafenib—thyroid cancer	0.000168	0.00134	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000167	0.00133	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000167	0.00133	CcSEcCtD
Pemetrexed—DCK—Metabolism—NDUFA13—thyroid cancer	0.000165	0.00389	CbGpPWpGaD
Pemetrexed—Pancytopenia—Epirubicin—thyroid cancer	0.000165	0.00131	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000164	0.00387	CbGpPWpGaD
Pemetrexed—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000164	0.0013	CcSEcCtD
Pemetrexed—Neutropenia—Epirubicin—thyroid cancer	0.000162	0.00129	CcSEcCtD
Pemetrexed—Dysphagia—Doxorubicin—thyroid cancer	0.00016	0.00128	CcSEcCtD
Pemetrexed—Nausea—Sorafenib—thyroid cancer	0.000159	0.00126	CcSEcCtD
Pemetrexed—DHFR—Disease—TRIM24—thyroid cancer	0.000158	0.00373	CbGpPWpGaD
Pemetrexed—Pancreatitis—Doxorubicin—thyroid cancer	0.000157	0.00125	CcSEcCtD
Pemetrexed—Angina pectoris—Doxorubicin—thyroid cancer	0.000156	0.00124	CcSEcCtD
Pemetrexed—DHFR—Metabolism—MINPP1—thyroid cancer	0.000156	0.00368	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CHST14—thyroid cancer	0.000155	0.00366	CbGpPWpGaD
Pemetrexed—Infestation NOS—Epirubicin—thyroid cancer	0.000155	0.00123	CcSEcCtD
Pemetrexed—Infestation—Epirubicin—thyroid cancer	0.000155	0.00123	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000153	0.00122	CcSEcCtD
Pemetrexed—Pancytopenia—Doxorubicin—thyroid cancer	0.000152	0.00121	CcSEcCtD
Pemetrexed—Renal failure—Epirubicin—thyroid cancer	0.000152	0.00121	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000152	0.00121	CcSEcCtD
Pemetrexed—Stomatitis—Epirubicin—thyroid cancer	0.000151	0.0012	CcSEcCtD
Pemetrexed—Conjunctivitis—Epirubicin—thyroid cancer	0.00015	0.0012	CcSEcCtD
Pemetrexed—Neutropenia—Doxorubicin—thyroid cancer	0.00015	0.00119	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—TPR—thyroid cancer	0.00015	0.00354	CbGpPWpGaD
Pemetrexed—GART—Metabolism—SLC5A5—thyroid cancer	0.000149	0.00352	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CHST14—thyroid cancer	0.000149	0.00351	CbGpPWpGaD
Pemetrexed—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000146	0.00116	CcSEcCtD
Pemetrexed—Agranulocytosis—Epirubicin—thyroid cancer	0.000144	0.00115	CcSEcCtD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000144	0.00341	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000143	0.00338	CbGpPWpGaD
Pemetrexed—Infestation NOS—Doxorubicin—thyroid cancer	0.000143	0.00114	CcSEcCtD
Pemetrexed—Infestation—Doxorubicin—thyroid cancer	0.000143	0.00114	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000142	0.00113	CcSEcCtD
Pemetrexed—DHFR—Disease—TRIM33—thyroid cancer	0.000141	0.00333	CbGpPWpGaD
Pemetrexed—Renal failure—Doxorubicin—thyroid cancer	0.000141	0.00112	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.00014	0.00112	CcSEcCtD
Pemetrexed—Stomatitis—Doxorubicin—thyroid cancer	0.000139	0.00111	CcSEcCtD
Pemetrexed—Conjunctivitis—Doxorubicin—thyroid cancer	0.000139	0.00111	CcSEcCtD
Pemetrexed—Hepatitis—Epirubicin—thyroid cancer	0.000139	0.00111	CcSEcCtD
Pemetrexed—ATIC—Metabolism—TPR—thyroid cancer	0.000138	0.00326	CbGpPWpGaD
Pemetrexed—Pharyngitis—Epirubicin—thyroid cancer	0.000138	0.0011	CcSEcCtD
Pemetrexed—Urinary tract disorder—Epirubicin—thyroid cancer	0.000137	0.00109	CcSEcCtD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000136	0.00322	CbGpPWpGaD
Pemetrexed—Urethral disorder—Epirubicin—thyroid cancer	0.000136	0.00108	CcSEcCtD
Pemetrexed—TYMS—Metabolism—MINPP1—thyroid cancer	0.000136	0.00321	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PRKAR1A—thyroid cancer	0.000136	0.0032	CbGpPWpGaD
Pemetrexed—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000135	0.00108	CcSEcCtD
Pemetrexed—DHFR—Folate Metabolism—TP53—thyroid cancer	0.000135	0.00318	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000134	0.00318	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TPR—thyroid cancer	0.000134	0.00317	CbGpPWpGaD
Pemetrexed—Agranulocytosis—Doxorubicin—thyroid cancer	0.000134	0.00106	CcSEcCtD
Pemetrexed—DHFR—Metabolism—NDUFA13—thyroid cancer	0.000132	0.00313	CbGpPWpGaD
Pemetrexed—Erythema multiforme—Epirubicin—thyroid cancer	0.000131	0.00105	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—TPR—thyroid cancer	0.000131	0.00309	CbGpPWpGaD
Pemetrexed—Eye disorder—Epirubicin—thyroid cancer	0.00013	0.00103	CcSEcCtD
Pemetrexed—Hepatitis—Doxorubicin—thyroid cancer	0.000128	0.00102	CcSEcCtD
Pemetrexed—SLC46A1—Disease—TPR—thyroid cancer	0.000128	0.00303	CbGpPWpGaD
Pemetrexed—Pharyngitis—Doxorubicin—thyroid cancer	0.000127	0.00102	CcSEcCtD
Pemetrexed—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000127	0.00101	CcSEcCtD
Pemetrexed—SLC46A1—Disease—PRKAR1A—thyroid cancer	0.000126	0.00298	CbGpPWpGaD
Pemetrexed—Urethral disorder—Doxorubicin—thyroid cancer	0.000126	0.001	CcSEcCtD
Pemetrexed—GART—Metabolism—RXRA—thyroid cancer	0.000125	0.00296	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—HPGD—thyroid cancer	0.000125	0.00295	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CHST14—thyroid cancer	0.000124	0.00294	CbGpPWpGaD
Pemetrexed—Arrhythmia—Epirubicin—thyroid cancer	0.000124	0.000987	CcSEcCtD
Pemetrexed—Alopecia—Epirubicin—thyroid cancer	0.000123	0.000977	CcSEcCtD
Pemetrexed—Erythema multiforme—Doxorubicin—thyroid cancer	0.000121	0.000967	CcSEcCtD
Pemetrexed—Malnutrition—Epirubicin—thyroid cancer	0.000121	0.000962	CcSEcCtD
Pemetrexed—Erythema—Epirubicin—thyroid cancer	0.000121	0.000962	CcSEcCtD
Pemetrexed—SLC46A1—Disease—MEN1—thyroid cancer	0.000121	0.00285	CbGpPWpGaD
Pemetrexed—Eye disorder—Doxorubicin—thyroid cancer	0.00012	0.000956	CcSEcCtD
Pemetrexed—Dysgeusia—Epirubicin—thyroid cancer	0.000118	0.000942	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—TPR—thyroid cancer	0.000117	0.00276	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NDUFA13—thyroid cancer	0.000116	0.00273	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CCND1—thyroid cancer	0.000115	0.00273	CbGpPWpGaD
Pemetrexed—Arrhythmia—Doxorubicin—thyroid cancer	0.000115	0.000914	CcSEcCtD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000114	0.0027	CbGpPWpGaD
Pemetrexed—Alopecia—Doxorubicin—thyroid cancer	0.000113	0.000904	CcSEcCtD
Pemetrexed—Malnutrition—Doxorubicin—thyroid cancer	0.000112	0.00089	CcSEcCtD
Pemetrexed—Erythema—Doxorubicin—thyroid cancer	0.000112	0.00089	CcSEcCtD
Pemetrexed—Anaemia—Epirubicin—thyroid cancer	0.000112	0.000889	CcSEcCtD
Pemetrexed—Dysgeusia—Doxorubicin—thyroid cancer	0.000109	0.000872	CcSEcCtD
Pemetrexed—TYMS—Metabolism—CHST14—thyroid cancer	0.000109	0.00256	CbGpPWpGaD
Pemetrexed—Syncope—Epirubicin—thyroid cancer	0.000108	0.000863	CcSEcCtD
Pemetrexed—Leukopenia—Epirubicin—thyroid cancer	0.000108	0.000861	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000108	0.00255	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—TPR—thyroid cancer	0.000107	0.00254	CbGpPWpGaD
Pemetrexed—Loss of consciousness—Epirubicin—thyroid cancer	0.000106	0.000846	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—PRKAR1A—thyroid cancer	0.000106	0.0025	CbGpPWpGaD
Pemetrexed—Hypertension—Epirubicin—thyroid cancer	0.000104	0.000831	CcSEcCtD
Pemetrexed—Anaemia—Doxorubicin—thyroid cancer	0.000103	0.000823	CcSEcCtD
Pemetrexed—ATIC—Metabolism—SLC5A5—thyroid cancer	0.000103	0.00244	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—PPARG—thyroid cancer	0.000103	0.00243	CbGpPWpGaD
Pemetrexed—Arthralgia—Epirubicin—thyroid cancer	0.000103	0.000819	CcSEcCtD
Pemetrexed—Myalgia—Epirubicin—thyroid cancer	0.000103	0.000819	CcSEcCtD
Pemetrexed—Chest pain—Epirubicin—thyroid cancer	0.000103	0.000819	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000102	0.000814	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.000102	0.0024	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CCND1—thyroid cancer	0.000101	0.00238	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—HPGD—thyroid cancer	0.0001	0.00237	CbGpPWpGaD
Pemetrexed—Syncope—Doxorubicin—thyroid cancer	0.0001	0.000798	CcSEcCtD
Pemetrexed—Leukopenia—Doxorubicin—thyroid cancer	0.0001	0.000797	CcSEcCtD
Pemetrexed—Anaphylactic shock—Epirubicin—thyroid cancer	9.86e-05	0.000785	CcSEcCtD
Pemetrexed—Oedema—Epirubicin—thyroid cancer	9.86e-05	0.000785	CcSEcCtD
Pemetrexed—Loss of consciousness—Doxorubicin—thyroid cancer	9.83e-05	0.000782	CcSEcCtD
Pemetrexed—Infection—Epirubicin—thyroid cancer	9.8e-05	0.00078	CcSEcCtD
Pemetrexed—Shock—Epirubicin—thyroid cancer	9.7e-05	0.000773	CcSEcCtD
Pemetrexed—Nervous system disorder—Epirubicin—thyroid cancer	9.67e-05	0.00077	CcSEcCtD
Pemetrexed—Thrombocytopenia—Epirubicin—thyroid cancer	9.66e-05	0.000769	CcSEcCtD
Pemetrexed—Hypertension—Doxorubicin—thyroid cancer	9.65e-05	0.000769	CcSEcCtD
Pemetrexed—SLC46A1—Disease—CALCA—thyroid cancer	9.61e-05	0.00227	CbGpPWpGaD
Pemetrexed—Skin disorder—Epirubicin—thyroid cancer	9.58e-05	0.000763	CcSEcCtD
Pemetrexed—Myalgia—Doxorubicin—thyroid cancer	9.52e-05	0.000758	CcSEcCtD
Pemetrexed—Chest pain—Doxorubicin—thyroid cancer	9.52e-05	0.000758	CcSEcCtD
Pemetrexed—Arthralgia—Doxorubicin—thyroid cancer	9.52e-05	0.000758	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	9.45e-05	0.000753	CcSEcCtD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	9.43e-05	0.00223	CbGpPWpGaD
Pemetrexed—Anorexia—Epirubicin—thyroid cancer	9.4e-05	0.000749	CcSEcCtD
Pemetrexed—DHFR—Disease—TCF7L1—thyroid cancer	9.4e-05	0.00222	CbGpPWpGaD
Pemetrexed—Anaphylactic shock—Doxorubicin—thyroid cancer	9.13e-05	0.000727	CcSEcCtD
Pemetrexed—Oedema—Doxorubicin—thyroid cancer	9.13e-05	0.000727	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—CDK1—thyroid cancer	9.09e-05	0.00215	CbGpPWpGaD
Pemetrexed—Infection—Doxorubicin—thyroid cancer	9.07e-05	0.000722	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Epirubicin—thyroid cancer	8.99e-05	0.000715	CcSEcCtD
Pemetrexed—Shock—Doxorubicin—thyroid cancer	8.98e-05	0.000715	CcSEcCtD
Pemetrexed—Nervous system disorder—Doxorubicin—thyroid cancer	8.95e-05	0.000713	CcSEcCtD
Pemetrexed—Thrombocytopenia—Doxorubicin—thyroid cancer	8.93e-05	0.000711	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDK1—thyroid cancer	8.87e-05	0.00209	CbGpPWpGaD
Pemetrexed—Skin disorder—Doxorubicin—thyroid cancer	8.86e-05	0.000706	CcSEcCtD
Pemetrexed—Dyspnoea—Epirubicin—thyroid cancer	8.79e-05	0.0007	CcSEcCtD
Pemetrexed—TYMS—Metabolism—HPGD—thyroid cancer	8.75e-05	0.00207	CbGpPWpGaD
Pemetrexed—Anorexia—Doxorubicin—thyroid cancer	8.7e-05	0.000693	CcSEcCtD
Pemetrexed—SLC46A1—Disease—CDK1—thyroid cancer	8.69e-05	0.00205	CbGpPWpGaD
Pemetrexed—Dyspepsia—Epirubicin—thyroid cancer	8.68e-05	0.000691	CcSEcCtD
Pemetrexed—ATIC—Metabolism—RXRA—thyroid cancer	8.68e-05	0.00205	CbGpPWpGaD
Pemetrexed—Decreased appetite—Epirubicin—thyroid cancer	8.57e-05	0.000683	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Epirubicin—thyroid cancer	8.51e-05	0.000678	CcSEcCtD
Pemetrexed—Fatigue—Epirubicin—thyroid cancer	8.5e-05	0.000677	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	8.45e-05	0.00199	CbGpPWpGaD
Pemetrexed—Constipation—Epirubicin—thyroid cancer	8.43e-05	0.000672	CcSEcCtD
Pemetrexed—Pain—Epirubicin—thyroid cancer	8.43e-05	0.000672	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	8.31e-05	0.000662	CcSEcCtD
Pemetrexed—Dyspnoea—Doxorubicin—thyroid cancer	8.14e-05	0.000648	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Epirubicin—thyroid cancer	8.06e-05	0.000642	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—SLC5A5—thyroid cancer	8.04e-05	0.0019	CbGpPWpGaD
Pemetrexed—Dyspepsia—Doxorubicin—thyroid cancer	8.03e-05	0.00064	CcSEcCtD
Pemetrexed—Decreased appetite—Doxorubicin—thyroid cancer	7.93e-05	0.000632	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—CDK1—thyroid cancer	7.93e-05	0.00187	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PPARG—thyroid cancer	7.9e-05	0.00187	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Doxorubicin—thyroid cancer	7.88e-05	0.000627	CcSEcCtD
Pemetrexed—Fatigue—Doxorubicin—thyroid cancer	7.87e-05	0.000626	CcSEcCtD
Pemetrexed—Urticaria—Epirubicin—thyroid cancer	7.83e-05	0.000624	CcSEcCtD
Pemetrexed—Pain—Doxorubicin—thyroid cancer	7.8e-05	0.000621	CcSEcCtD
Pemetrexed—Constipation—Doxorubicin—thyroid cancer	7.8e-05	0.000621	CcSEcCtD
Pemetrexed—Abdominal pain—Epirubicin—thyroid cancer	7.8e-05	0.000621	CcSEcCtD
Pemetrexed—Body temperature increased—Epirubicin—thyroid cancer	7.8e-05	0.000621	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	7.63e-05	0.0018	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Doxorubicin—thyroid cancer	7.46e-05	0.000594	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	7.37e-05	0.00174	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Epirubicin—thyroid cancer	7.27e-05	0.000579	CcSEcCtD
Pemetrexed—Urticaria—Doxorubicin—thyroid cancer	7.25e-05	0.000577	CcSEcCtD
Pemetrexed—Abdominal pain—Doxorubicin—thyroid cancer	7.21e-05	0.000574	CcSEcCtD
Pemetrexed—Body temperature increased—Doxorubicin—thyroid cancer	7.21e-05	0.000574	CcSEcCtD
Pemetrexed—DCK—Metabolism—TPR—thyroid cancer	7.17e-05	0.00169	CbGpPWpGaD
Pemetrexed—Asthenia—Epirubicin—thyroid cancer	7.08e-05	0.000563	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—PTEN—thyroid cancer	7.07e-05	0.00167	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PRKAR1A—thyroid cancer	7.05e-05	0.00167	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NRG1—thyroid cancer	6.98e-05	0.00165	CbGpPWpGaD
Pemetrexed—Pruritus—Epirubicin—thyroid cancer	6.98e-05	0.000556	CcSEcCtD
Pemetrexed—DHFR—Disease—TPR—thyroid cancer	6.88e-05	0.00162	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PRKAR1A—thyroid cancer	6.77e-05	0.0016	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—RXRA—thyroid cancer	6.76e-05	0.0016	CbGpPWpGaD
Pemetrexed—Diarrhoea—Epirubicin—thyroid cancer	6.75e-05	0.000537	CcSEcCtD
Pemetrexed—Hypersensitivity—Doxorubicin—thyroid cancer	6.72e-05	0.000535	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—TERT—thyroid cancer	6.55e-05	0.00155	CbGpPWpGaD
Pemetrexed—Asthenia—Doxorubicin—thyroid cancer	6.55e-05	0.000521	CcSEcCtD
Pemetrexed—Dizziness—Epirubicin—thyroid cancer	6.52e-05	0.000519	CcSEcCtD
Pemetrexed—DHFR—Disease—MEN1—thyroid cancer	6.47e-05	0.00153	CbGpPWpGaD
Pemetrexed—Pruritus—Doxorubicin—thyroid cancer	6.46e-05	0.000514	CcSEcCtD
Pemetrexed—Vomiting—Epirubicin—thyroid cancer	6.27e-05	0.000499	CcSEcCtD
Pemetrexed—SLC46A1—Disease—TERT—thyroid cancer	6.27e-05	0.00148	CbGpPWpGaD
Pemetrexed—Diarrhoea—Doxorubicin—thyroid cancer	6.24e-05	0.000497	CcSEcCtD
Pemetrexed—Rash—Epirubicin—thyroid cancer	6.22e-05	0.000495	CcSEcCtD
Pemetrexed—GART—Metabolism—PTGS2—thyroid cancer	6.22e-05	0.00147	CbGpPWpGaD
Pemetrexed—Dermatitis—Epirubicin—thyroid cancer	6.21e-05	0.000495	CcSEcCtD
Pemetrexed—Dizziness—Doxorubicin—thyroid cancer	6.03e-05	0.00048	CcSEcCtD
Pemetrexed—SLC46A1—Disease—HIF1A—thyroid cancer	5.99e-05	0.00142	CbGpPWpGaD
Pemetrexed—Nausea—Epirubicin—thyroid cancer	5.86e-05	0.000466	CcSEcCtD
Pemetrexed—Vomiting—Doxorubicin—thyroid cancer	5.8e-05	0.000462	CcSEcCtD
Pemetrexed—DHFR—Metabolism—TPR—thyroid cancer	5.76e-05	0.00136	CbGpPWpGaD
Pemetrexed—Rash—Doxorubicin—thyroid cancer	5.75e-05	0.000458	CcSEcCtD
Pemetrexed—Dermatitis—Doxorubicin—thyroid cancer	5.75e-05	0.000458	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—TERT—thyroid cancer	5.71e-05	0.00135	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PRKAR1A—thyroid cancer	5.67e-05	0.00134	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	5.66e-05	0.00134	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PPARG—thyroid cancer	5.48e-05	0.00129	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PTEN—thyroid cancer	5.42e-05	0.00128	CbGpPWpGaD
Pemetrexed—Nausea—Doxorubicin—thyroid cancer	5.42e-05	0.000432	CcSEcCtD
Pemetrexed—DCK—Metabolism—SLC5A5—thyroid cancer	5.37e-05	0.00127	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CALCA—thyroid cancer	5.15e-05	0.00122	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—TPR—thyroid cancer	5.03e-05	0.00119	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	5.03e-05	0.00119	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—BRAF—thyroid cancer	4.96e-05	0.00117	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PRKAR1A—thyroid cancer	4.95e-05	0.00117	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—TP53—thyroid cancer	4.83e-05	0.00114	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDK1—thyroid cancer	4.66e-05	0.0011	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—RXRA—thyroid cancer	4.51e-05	0.00106	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—SLC5A5—thyroid cancer	4.31e-05	0.00102	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTGS2—thyroid cancer	4.31e-05	0.00102	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PPARG—thyroid cancer	4.27e-05	0.00101	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.24e-05	0.001	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND1—thyroid cancer	4.23e-05	0.001	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTGS2—thyroid cancer	4.01e-05	0.000946	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND1—thyroid cancer	3.79e-05	0.000894	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SLC5A5—thyroid cancer	3.76e-05	0.000889	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTEN—thyroid cancer	3.76e-05	0.000887	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NRG1—thyroid cancer	3.74e-05	0.000884	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND1—thyroid cancer	3.69e-05	0.000872	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—RXRA—thyroid cancer	3.62e-05	0.000856	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTEN—thyroid cancer	3.5e-05	0.000825	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TERT—thyroid cancer	3.36e-05	0.000793	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTGS2—thyroid cancer	3.36e-05	0.000793	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND1—thyroid cancer	3.3e-05	0.00078	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HIF1A—thyroid cancer	3.21e-05	0.000759	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—RXRA—thyroid cancer	3.16e-05	0.000747	CbGpPWpGaD
Pemetrexed—GART—Metabolism—AKT1—thyroid cancer	3.12e-05	0.000738	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NRAS—thyroid cancer	3.12e-05	0.000736	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTEN—thyroid cancer	2.93e-05	0.000691	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PPARG—thyroid cancer	2.85e-05	0.000672	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—KRAS—thyroid cancer	2.68e-05	0.000634	CbGpPWpGaD
Pemetrexed—DHFR—Disease—BRAF—thyroid cancer	2.66e-05	0.000628	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TP53—thyroid cancer	2.49e-05	0.000589	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PPARG—thyroid cancer	2.29e-05	0.00054	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—HRAS—thyroid cancer	2.28e-05	0.000539	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTGS2—thyroid cancer	2.24e-05	0.000529	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TP53—thyroid cancer	2.18e-05	0.000514	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—AKT1—thyroid cancer	2.17e-05	0.000511	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTGS2—thyroid cancer	2.15e-05	0.000507	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—AKT1—thyroid cancer	2.01e-05	0.000476	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PPARG—thyroid cancer	2e-05	0.000471	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTEN—thyroid cancer	1.95e-05	0.000461	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTEN—thyroid cancer	1.87e-05	0.000443	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTGS2—thyroid cancer	1.8e-05	0.000425	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—AKT1—thyroid cancer	1.69e-05	0.000398	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NRAS—thyroid cancer	1.67e-05	0.000395	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTGS2—thyroid cancer	1.57e-05	0.000371	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTEN—thyroid cancer	1.57e-05	0.000371	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KRAS—thyroid cancer	1.44e-05	0.00034	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTEN—thyroid cancer	1.37e-05	0.000323	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HRAS—thyroid cancer	1.22e-05	0.000289	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—AKT1—thyroid cancer	1.13e-05	0.000266	CbGpPWpGaD
Pemetrexed—DHFR—Disease—AKT1—thyroid cancer	1.08e-05	0.000255	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—AKT1—thyroid cancer	9.05e-06	0.000214	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—AKT1—thyroid cancer	7.89e-06	0.000186	CbGpPWpGaD
